Systemic Metabolomic Changes in Idiopathic Intracranial Hypertension
Open Access
- 1 September 2026
- journal article
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000119
Abstract
Background and ObjectivesObesity is a well-established risk factor for idiopathic intracranial hypertension (IIH), yet the metabolic mechanisms linking obesity to IIH remain poorly understood. Prev...Keywords
This publication has 42 references indexed in Scilit:
- GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a TrialJAMA Neurology, 2025
- Current Understanding of the Pathophysiology of Idiopathic Intracranial HypertensionCurrent Neurology and Neuroscience Reports, 2025
- Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)Atherosclerosis, 2024
- Metabolic Dysfunction in New‐Onset Idiopathic Intracranial Hypertension: Identification of Novel BiomarkersAnnals of Neurology, 2024
- Role of the glymphatic system in idiopathic intracranial hypertensionClinical Neurology and Neurosurgery, 2022
- Role of ceramides in the pathogenesis of diabetes mellitus and its complicationsJournal of Diabetes and its Complications, 2020
- Cysteine and homocysteine as biomarker of various diseasesFood Science & Nutrition, 2020
- Plasma High‐Resolution Metabolomics Differentiates Adults with Normal Weight Obesity from Lean IndividualsObesity, 2019
- The Idiopathic Intracranial Hypertension Treatment TrialJAMA Neurology, 2014
- Antidepressant drugs affect dopamine uptakeBiochemical Pharmacology, 1975